Comparative metabolism of tramadol and tapentadol: a toxicological perspective

References

• Afilalo M, Stegmann JU, Upmalis D. (2010). Tapentadol immediate release: a new treatment option for acute pain management. J Pain Res 3:1–9.
   PubMedGoogle Scholar
• Bouhifd M, Hartung T, Hogberg HT, et al. (2013). Review: toxicometabolomics. J Appl Toxicol 33:1365–1383.
   PubMed Web of Science ®Google Scholar
• Bourland JA, Collins AA, Chester SA, et al. (2010). Determination of tapentadol (Nucynta®) and N-desmethyltapentadol in authentic urine specimens by ultra-performance liquid chromatography-tandem mass spectrometry. J Anal Toxicol 34:450–457.
   PubMed Web of Science ®Google Scholar
• Burchell B, Coughtrie MW. (1997). Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. Environ Health Perspect 105 Suppl 4:739–747.
   PubMed Web of Science ®Google Scholar
• Campanero MA, Garcia-Quetglas E, Sadaba B, Azanza JR. (2004). Simultaneous stereoselective analysis of tramadol and its primary phase I metabolites in plasma by liquid chromatography. Application to a pharmacokinetic study in humans. J Chromatogr A 1031:219–228.
   PubMed Web of Science ®Google Scholar
• Carlquist JF, Moody DE, Knight S, et al. (2015). A possible mechanistic link between the CYP2C19 genotype, the methadone metabolite ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP), and methadone-induced corrected QT interval prolongation in a pilot study. Mol Diagn Ther 19:131–138.
   PubMed Web of Science ®Google Scholar
• Cavallari LH, Jeong H, Bress A. (2011). Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med 4:123–136.
   PubMedGoogle Scholar
• Coulter C, Taruc M, Tuyay J, Moore C. (2010). Determination of tapentadol and its metabolite N-desmethyltapentadol in urine and oral fluid using liquid chromatography with tandem mass spectral detection. J Anal Toxicol 34:458–463.
   PubMed Web of Science ®Google Scholar
• Court MH, Krishnaswamy S, Hao Q, et al. (2003). Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125–1133.
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, et al. (2006). ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80:668–681.
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, et al. (2005). Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78:593–604.
   PubMed Web of Science ®Google Scholar
• Daniels J, Kadlubar S. (2013). Sulfotransferase genetic variation: from cancer risk to treatment response. Drug Metab Rev 45:415–422.
   PubMed Web of Science ®Google Scholar
• Darbari DS, van Schaik RH, Capparelli EV, et al. (2008). UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease . Am J Hematol 83:200–202.
   PubMed Web of Science ®Google Scholar
• Dennis BB, Bawor M, Thabane L, et al. (2014). Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis. PLoS One 9:e86114.
   PubMed Web of Science ®Google Scholar
• DePriest AZ, Puet BL, Holt AC, et al. (2015). Metabolism and disposition of prescription opioids: a review. Forensic Sci Rev 27:115–145.
   PubMedGoogle Scholar
• Dinis-Oliveira RJ. (2014). Metabolomics of drugs of abuse: a more realistic view of the toxicological complexity. Bioanalysis 6:3155–3159.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2015). Metabolomics of cocaine: implications in toxicity. Toxicol Mech Methods 25:494–500.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2016a). Metabolomics of Δ9-tetrahydrocannabinol: implications in toxicity. Drug Metab Rev 48:80–87.
   PubMed Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2016b). Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response. Drug Metab Rev. [Epub ahead of print]. doi: 10.1080/03602532.2016.1192642.
   Web of Science ®Google Scholar
• Dinis-Oliveira RJ. (2016c). Oxidative and non-oxidative metabolomics of ethanol. Curr Drug Metab 17:327–335.
   PubMed Web of Science ®Google Scholar
• Dousa M, Lehnert P, Adamusova H, Bosakova Z. (2013). Fundamental study of enantioselective HPLC separation of tapentadol enantiomers using cellulose-based chiral stationary phase in normal phase mode. J Pharm Biomed Anal 74:111–116.
   PubMed Web of Science ®Google Scholar
• Duthie DJ. (1998). Remifentanil and tramadol. Br J Anaesth 81:51–57.
   PubMed Web of Science ®Google Scholar
• Eagle K. (2012). Hypothesis: holiday sudden cardiac death: food and alcohol inhibition of SULT1A enzymes as a precipitant. J Appl Toxicol 32:751–755.
   PubMed Web of Science ®Google Scholar
• Eissing T, Lippert J, Willmann S. (2012). Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition. Mol Diagn Ther 16:43–53.
   PubMed Web of Science ®Google Scholar
• Faria J, Barbosa J, Queiros O, et al. (2016). Comparative study of the neurotoxicological effects of tramadol and tapentadol in SH-SY5Y cells. Toxicology 359–360:1–10.
   PubMed Web of Science ®Google Scholar
• Gadel S, Crafford A, Regina K, Kharasch ED. (2013). Methadone N-demethylation by the common CYP2B6 allelic variant CYP2B6.6. Drug Metab Dispos 41:709–713.
   PubMed Web of Science ®Google Scholar
• Gadel S, Friedel C, Kharasch ED. (2015). Differences in Methadone Metabolism by CYP2B6 Variants. Drug Metab Dispos 43:994–1001.
   PubMed Web of Science ®Google Scholar
• Gamage N, Barnett A, Hempel N, et al. (2006). Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 90:5–22.
   PubMed Web of Science ®Google Scholar
• Garcia-Quetglas E, Azanza JR, Sadaba B, et al. (2007). Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol Res 55:122–130.
   PubMed Web of Science ®Google Scholar
• Gillen C, Haurand M, Kobelt DJ, Wnendt S. (2000). Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol 362:116–121.
   PubMed Web of Science ®Google Scholar
• Gillman PK. (2005). Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 95:434–441.
   PubMed Web of Science ®Google Scholar
• Giorgi M. (2012). Tramadol vs Tapentadol: A new Horizon in Pain Treatment? Am J Anim Vet Sci 7:7–11.
   Google Scholar
• Giorgi M, Meizler A, Mills PC. (2012a). Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs. Vet J 194:309–313.
   PubMed Web of Science ®Google Scholar
• Giorgi M, Meizler A, Mills PC. (2012b). Quantification of tapentadol in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. J Pharm Biomed Anal 67-68:148–153.
   PubMed Web of Science ®Google Scholar
• Gohler K, Brett M, Smit JW, et al. (2013). Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. Int J Clin Pharmacol Ther 51:338–348.
   PubMed Web of Science ®Google Scholar
• Gong L, Stamer UM, Tzvetkov MV, et al. (2014). PharmGKB summary: tramadol pathway. Pharmacogenet Genomics 24:374–380.
   PubMed Web of Science ®Google Scholar
• Grond S, Sablotzki A. (2004). Clinical pharmacology of tramadol. Clin Pharmacokinet 43:879–923.
   PubMed Web of Science ®Google Scholar
• Grun B, Merkel U, Riedel KD, et al. (2012). Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine. Br J Clin Pharmacol 74:854–863.
   PubMed Web of Science ®Google Scholar
• Guay DR. (2009). Is tapentadol an advance on tramadol? Consult Pharm 24:833–840.
   PubMedGoogle Scholar
• Han Y, Li L, Zhang Y, et al. (2015). Phenomics of vascular disease: the systematic approach to the combination therapy. Curr Vasc Pharmacol 13:433–440.
   PubMed Web of Science ®Google Scholar
• Harrison C, Smart D, Lambert DG. (1998). Stimulatory effects of opioids. Br J Anaesth 81:20–28.
   PubMed Web of Science ®Google Scholar
• Hartrick CT, Rodriguez Hernandez JR. (2012). Tapentadol for pain: a treatment evaluation. Expert Opin Pharmacother 13:283–286.
   PubMed Web of Science ®Google Scholar
• Hartrick CT, Rozek RJ. (2011). Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor. CNS Drugs 25:359–370.
   PubMed Web of Science ®Google Scholar
• Hu Z, Deng Y, Hu C, et al. (2012). ¹H NMR-based metabonomic analysis of brain in rats of morphine dependence and withdrawal intervention. Behav Brain Res 231:11–19.
   PubMed Web of Science ®Google Scholar
• Hui-Chen L, Yang Y, Na W, et al. (2004). Pharmacokinetics of the enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in healthy male and female chinese volunteers. Chirality 16:112–118.
   PubMed Web of Science ®Google Scholar
• Jancova P, Anzenbacher P, Anzenbacherova E. (2010). Phase II drug metabolizing enzymes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:103–116.
   PubMed Web of Science ®Google Scholar
• Joly P, Gagnieu MC, Bardel C, et al. (2012). Genotypic screening of the main opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. Am J Hematol 87:534–536.
   PubMed Web of Science ®Google Scholar
• Kell DB, Goodacre R. (2014). Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. Drug Discov Today 19:171–182.
   PubMed Web of Science ®Google Scholar
• Kemp W, Schlueter S, Smalley E. (2013). Death due to apparent intravenous injection of tapentadol. J Forensic Sci 58:288–291.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Regina KJ, Blood J, Friedel C. (2015). Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism. Anesthesiology 123:1142–1153.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Stubbert K. (2013). Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol 53:305–313.
   PubMed Web of Science ®Google Scholar
• Kneip C, Terlinden R, Beier H, Chen G. (2008). Investigations into the drug–drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett 2:67–75.
   PubMedGoogle Scholar
• Kogel B, Terlinden R, Schneider J. (2014). Characterisation of tramadol, morphine and tapentadol in an acute pain model in Beagle dogs. Vet Anaesth Analg 41:297–304.
   PubMed Web of Science ®Google Scholar
• Kosten TR, George TP. (2002). The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect 1:13–20.
   PubMedGoogle Scholar
• Kress HG. (2010). Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 14:781–783.
   PubMed Web of Science ®Google Scholar
• KuKanich B, Papich MG. (2004). Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. J Vet Pharmacol Ther 27:239–246.
   PubMed Web of Science ®Google Scholar
• Lai J, Ma SW, Porreca F, Raffa RB. (1996). Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells. Eur J Pharmacol 316:369–372.
   PubMed Web of Science ®Google Scholar
• Larson SJ, Pestaner J, Prashar SK, et al. (2012). Postmortem distribution of tapentadol and N-desmethyltapentadol. J Anal Toxicol 36:440–443.
   PubMed Web of Science ®Google Scholar
• Lassen D, Damkier P, Brosen K. (2015). The pharmacogenetics of tramadol. Clin Pharmacokinet 54:825–836.
   PubMed Web of Science ®Google Scholar
• Laugesen S, Enggaard TP, Pedersen RS, et al. (2005). Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther 77:312–323.
   PubMed Web of Science ®Google Scholar
• Lee CR, McTavish D, Sorkin EM. (1993). Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 46:313–340.
   PubMed Web of Science ®Google Scholar
• Lee HK, Lebkowska-Wieruszewska B, Kim TW, et al. (2013). Pharmacokinetics of the novel atypical opioid tapentadol after intravenous, intramuscular and subcutaneous administration in cats. Vet J 198:620–624.
   PubMed Web of Science ®Google Scholar
• Lehtonen P, Sten T, Aitio O, et al. (2010). Glucuronidation of racemic O-desmethyltramadol, the active metabolite of tramadol. Eur J Pharm Sci 41:523–530.
   PubMed Web of Science ®Google Scholar
• Leppert W. (2011). CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology 87:274–285.
   PubMed Web of Science ®Google Scholar
• Levo A, Koski A, Ojanpera I, et al. (2003). Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. Forensic Sci Int 135:9–15.
   PubMed Web of Science ®Google Scholar
• Levran O, Peles E, Hamon S, et al. (2013). CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol 18:709–716.
   PubMed Web of Science ®Google Scholar
• Li S, Todor A, Luo R. (2016). Blood transcriptomics and metabolomics for personalized medicine. Comput Struct Biotechnol J 14:1–7.
   PubMed Web of Science ®Google Scholar
• Lotsch J, Skarke C, Liefhold J, Geisslinger G. (2004). Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 43:983–1013.
   PubMed Web of Science ®Google Scholar
• Madadi P, Sistonen J, Silverman G, et al. (2013). Life-threatening adverse events following therapeutic opioid administration in adults: is pharmacogenetic analysis useful? Pain Res Manag 18:133–136.
   PubMed Web of Science ®Google Scholar
• Mahdy T, El-Shihi TH, Emara MM, et al. (2012a). Development and validation of a new GC-MS method for the detection of tramadol, O-desmethyltramadol, 6-acetylmorphine and morphine in blood, brain, liver and kidney of Wistar rats treated with the combination of heroin and tramadol. J Anal Toxicol 36:548–559.
   PubMed Web of Science ®Google Scholar
• Mahdy T, El-Shihi TH, Emara MM, Giorgi M. (2012b). New HPLC method to detect individual opioids (heroin and tramadol) and their metabolites in the blood of rats on combination treatment. J Chromatogr Sci 50:658–665.
   PubMed Web of Science ®Google Scholar
• Mannelli P, Patkar A, Rozen S, et al. (2009). Opioid use affects antioxidant activity and purine metabolism: preliminary results. Hum Psychopharmacol 24:666–675.
   PubMed Web of Science ®Google Scholar
• Matic M, Norman E, Rane A, et al. (2014). Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort. Pharmacogenomics 15:1589–1597.
   PubMed Web of Science ®Google Scholar
• McClay JL, Adkins DE, Vunck SA, et al. (2013). Large-scale neurochemical metabolomics analysis identifies multiple compounds associated with methamphetamine exposure. Metabolomics 9:392–402.
   PubMed Web of Science ®Google Scholar
• Mehvar R, Elliott K, Parasrampuria R, Eradiri O. (2007). Stereospecific high-performance liquid chromatographic analysis of tramadol and its O-demethylated (M1) and N,O-demethylated (M5) metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 852:152–159.
   PubMed Web of Science ®Google Scholar
• Meng J, Zhang X, Wu H, et al. (2012). Morphine-induced conditioned place preference in mice: metabolomic profiling of brain tissue to find “molecular switch” of drug abuse by gas chromatography/mass spectrometry. Anal Chim Acta 710:125–130.
   PubMed Web of Science ®Google Scholar
• Mercier F, Claret L, Prins K, Bruno R. (2014). A model-based meta-analysis to compare efficacy and tolerability of tramadol and tapentadol for the treatment of chronic non-malignant pain. Pain Ther 3:31–44.
   PubMedGoogle Scholar
• Meske DS, Xie JY, Oyarzo J, et al. (2014). Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain. Neurosci Lett 562:91–96.
   PubMed Web of Science ®Google Scholar
• Mouly S, Bloch V, Peoc'h K, et al. (2015). Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. Br J Clin Pharmacol 79:967–977.
   PubMed Web of Science ®Google Scholar
• Nielsen AG, Pedersen RS, Noehr-Jensen L, et al. (2010). Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol's O-demethylation via CYP2D6. Eur J Clin Pharmacol 66:655–660.
   PubMed Web of Science ®Google Scholar
• Nimmagadda D, Cherala G, Ghatta S. (2006). Cytosolic sulfotransferases. Indian J Exp Biol 44:171–182.
   PubMedGoogle Scholar
• Noehr-Jensen L, Zwisler ST, Larsen F, et al. (2009). Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain. Clin Pharmacol Ther 86:626–633.
   PubMed Web of Science ®Google Scholar
• Oliveira A, Dinis-Oliveira RJ, Nogueira A, et al. (2014). Genetic profile and cancer-related pain: A tale from two outlier cases with bone metastatic disease. Pain Med 15:710–712.
   PubMed Web of Science ®Google Scholar
• Overholser BR, Foster DR. (2011). Opioid pharmacokinetic drug-drug interactions. Am J Manag Care 17 Suppl 11:S276–S287.
   PubMedGoogle Scholar
• Paar WD, Frankus P, Dengler HJ. (1992). The metabolism of tramadol by human liver microsomes. Clin Investig 70:708–710.
   PubMedGoogle Scholar
• Paar WD, Poche S, Gerloff J, Dengler HJ. (1997). Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 53:235–239.
   PubMed Web of Science ®Google Scholar
• Pedersen RS, Damkier P, Brosen K. (2006). Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol 62:513–521.
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Alegre C, Blake D, et al. (2012). Current considerations for the treatment of severe chronic pain: The potential for tapentadol. Pain Pract 12:290–306.
   PubMed Web of Science ®Google Scholar
• Pilgrim JL, Gerostamoulos D, Drummer OH. (2010). Deaths involving serotonergic drugs. Forensic Sci Int 198:110–117.
   PubMed Web of Science ®Google Scholar
• Pilgrim JL, Gerostamoulos D, Drummer OH. (2011). Deaths involving contraindicated and inappropriate combinations of serotonergic drugs. Int J Legal Med 125:803–815.
   PubMed Web of Science ®Google Scholar
• Power I. (2011). An update on analgesics. Br J Anaesth 107:19–24.
   PubMed Web of Science ®Google Scholar
• Raffa RB. (2008). Basic pharmacology relevant to drug abuse assessment: Tramadol as example. J Clin Pharm Ther 33:101–108.
   PubMed Web of Science ®Google Scholar
• Raffa RB, Buschmann H, Christoph T, et al. (2012). Mechanistic and functional differentiation of tapentadol and Tramadol. Expert Opin Pharmacother 13:1437–1449.
   PubMed Web of Science ®Google Scholar
• Ramirez T, Daneshian M, Kamp H, et al. (2013). Metabolomics in toxicology and preclinical research. ALTEX 30:209–225.
   PubMedGoogle Scholar
• Rouguieg K, Picard N, Sauvage FL, et al. (2010). Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 38:40–45.
   PubMed Web of Science ®Google Scholar
• Sanchez Del Aguila MJ, Schenk M, Kern KU, et al. (2015). Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain. Clin Ther 37:94–113.
   PubMed Web of Science ®Google Scholar
• Schroder W, Tzschentke TM, Terlinden R, et al. (2011). Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 337:312–320.
   PubMed Web of Science ®Google Scholar
• Scott LJ, Perry CM. (2000). Tramadol: A review of its use in perioperative pain. Drugs 60:139–176.
   PubMed Web of Science ®Google Scholar
• Singh DR, Nag K, Shetti AN, Krishnaveni N. (2013). Tapentadol hydrochloride: A novel analgesic. Saudi J Anaesth 7:322–326.
   PubMedGoogle Scholar
• Skinner-Robertson S, Fradette C, Bouchard S, et al. (2015). Pharmacokinetics of tramadol and O-desmethyltramadol enantiomers following administration of extended-release tablets to elderly and young subjects. Drugs Aging 32:1029–1043.
   PubMed Web of Science ®Google Scholar
• Smit JW, Oh C, Rengelshausen J, et al. (2010). Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug–drug interaction studies. Pharmacotherapy 30:25–34.
   PubMed Web of Science ®Google Scholar
• Smith HS. (2009). Opioid metabolism. Mayo Clin Proc 84:613–624.
   PubMed Web of Science ®Google Scholar
• Stamer UM, Musshoff F, Kobilay M, et al. (2007). Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 82:41–47.
   PubMed Web of Science ®Google Scholar
• Stamer UM, Stuber F. (2007). The pharmacogenetics of analgesia. Expert Opin Pharmacother 8:2235–2245.
   PubMed Web of Science ®Google Scholar
• Steigerwald I, Schenk M, Lahne U, et al. (2013). Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Clin Drug Investig 33:607–619.
   PubMed Web of Science ®Google Scholar
• Subrahmanyam V, Renwick AB, Walters DG, et al. (2001). Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 29:1146–1155.
   PubMed Web of Science ®Google Scholar
• Terlinden R, Kogel BY, Englberger W, Tzschentke TM. (2010). In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol 32:31–38.
   PubMedGoogle Scholar
• Terlinden R, Ossig J, Fliegert F, et al. (2007). Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet 32:163–169.
   PubMed Web of Science ®Google Scholar
• Tsutaoka BT, Ho RY, Fung SM, Kearney TE. (2015). Comparative toxicity of tapentadol and tramadol utilizing data reported to the national poison data system. Ann Pharmacother 49:1311–1316.
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kogel B, et al. (2007). (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 323:265–276.
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kogel BY. (2014). The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs 28:319–329.
   PubMed Web of Science ®Google Scholar
• Tzvetkov MV, Saadatmand AR, Lotsch J, et al. (2011). Genetically polymorphic OCT1: Another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther 90:143–150.
   PubMed Web of Science ®Google Scholar
• Unruh GE, Hamm S, Pw D, Dengler HJ. (1995). Isotope effects during metabolism of (+)− and (−)− trans tramadol isotopomers by human liver microsomes. Isotopes Environ Health Stud 31:247–253.
   Web of Science ®Google Scholar
• Vadivelu N, Mitra S, Narayan D. (2010). Recent advances in postoperative pain management. Yale J Biol Med 83:11–25.
   PubMedGoogle Scholar
• Wade WE, Spruill WJ. (2009). Tapentadol hydrochloride: a centrally acting oral analgesic. Clin Ther 31:2804–2818.
   PubMed Web of Science ®Google Scholar
• Wang SC, Ho IK, Tsou HH, et al. (2013). Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort. omics 17:519–526.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2012). Tapentadol Pre-Review Report, Expert Committee on Drug Dependence, Thirty-fifth Meeting. Hammamet, Tunisia, 4–8 June 2012.
   Google Scholar
• Wu WN, McKown LA, Gauthier AD, et al. (2001). Metabolism of the analgesic drug, tramadol hydrochloride, in rat and dog. Xenobiotica 31:423–441.
   PubMed Web of Science ®Google Scholar
• Wu WN, McKown LA, Liao S. (2002). Metabolism of the analgesic drug ULTRAM (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica 32:411–425.
   PubMed Web of Science ®Google Scholar
• Xia S, Persaud S, Birnbaum A. (2015). Exploratory study on association of single-nucleotide polymorphisms with hydromorphone analgesia in ED. Am J Emerg Med 33:444–447.
   PubMed Web of Science ®Google Scholar
• Zaitsu K, Hayashi Y, Kusano M, et al. (2016). Application of metabolomics to toxicology of drugs of abuse: a mini review of metabolomics approach to acute and chronic toxicity studies. Drug Metab Pharmacokinet 31:21–26.
   PubMed Web of Science ®Google Scholar
• Zaitsu K, Miyawaki I, Bando K, et al. (2014). Metabolic profiling of urine and blood plasma in rat models of drug addiction on the basis of morphine, methamphetamine, and cocaine-induced conditioned place preference. Anal Bioanal Chem 406:1339–1354.
   PubMed Web of Science ®Google Scholar
• Zhang M, Luo H, Xi Z, Rogaeva E. (2015). Drug repositioning for diabetes based on ‘omics’ data mining. PLoS One 10:e0126082.
   PubMed Web of Science ®Google Scholar
• Zheng T, Liu L, Aa J, et al. (2013). Metabolic phenotype of rats exposed to heroin and potential markers of heroin abuse. Drug Alcohol Depend 127:177–186.
   PubMed Web of Science ®Google Scholar
• Zhou SF. (2009a). Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 48:689–723.
   PubMed Web of Science ®Google Scholar
• Zhou SF. (2009b). Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clin Pharmacokinet 48:761–804.
   PubMed Web of Science ®Google Scholar